2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexQuality of lifeHigher epigenetic age accelerationTreatment-related symptomsOverall survivalEpigenetic age accelerationRadiation therapyRisk factorsClinical characteristicsNeck cancerAge accelerationWorse overall survivalHuman papilloma virusFaster biological agingAdverse eventsDistant metastasisLifestyle factorsMass indexCancer outcomesBlood biomarkersPapilloma virusFunctional assessmentHigher HRPatients
2015
National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database
Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyComorbidityDatabases, FactualFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPopulation SurveillanceRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesYoung AdultConceptsNational Cancer DatabaseSystemic therapyPalliative therapyTreatment patternsNeck cancerCancer DatabaseClinical trialsMedicaid/uninsured statusCox proportional hazards analysisCommon treatment regimenNational treatment patternsCharlson comorbidity scorePrimary disease siteRetrospective cohort analysisProportional hazards analysisRisk of deathNeck cancer patientsMedicare/Comorbidity scoreMetastatic headOverall survivalSystemic treatmentTreatment regimenDistant metastasisKaplan-MeierHuman Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials
Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.Peer-Reviewed Original ResearchConceptsClinical trialsRisk groupsHuman papillomavirus-associated oropharynx cancerHPV-negative OPCPoor-risk subsetTreatment-related morbidityDe-escalation trialsPrognostic risk groupsClinical trial optionsYounger median ageNew treatment strategiesIdeal patient groupNovel therapeutic targetInvasive surgical techniquesDeintensification trialsTreatment deintensificationOropharynx cancerSmoking exposureMetastatic diseaseModality therapyFavorable prognosisMedian ageBetter prognosisSuperior prognosisIntense therapy
2014
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen E. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 2014, 15: 469. PMID: 25432788, PMCID: PMC4289298, DOI: 10.1186/1745-6215-15-469.Peer-Reviewed Original ResearchMeSH KeywordsAfatinibAntineoplastic AgentsCarcinoma, Squamous CellChemoradiotherapyChemotherapy, AdjuvantClinical ProtocolsDisease-Free SurvivalDouble-Blind MethodErbB ReceptorsHead and Neck NeoplasmsHumansMolecular Targeted TherapyNeoplasm Recurrence, LocalNeoplasm StagingProtein Kinase InhibitorsQuality of LifeQuinazolinesResearch DesignRisk FactorsSquamous Cell Carcinoma of Head and NeckTime FactorsTreatment OutcomeConceptsEpidermal growth factor receptorDisease-free survivalErbB family membersAdvanced diseaseOropharynx cancerOverall survivalEndpoint measuresUnfavourable riskPrimary siteHigh-risk HNSCC patientsHPV-positive oropharynx cancerIrreversible ErbB family blockerDisease-free survival ratesRandomized phase II trialNeck squamous cell carcinomaErbB family blockerHigh-risk headHigh-risk HNSCCPrimary endpoint measureGood clinical conditionEvidence of diseaseLymph node involvementPhase II trialPhase III studyUnacceptable adverse eventsPhase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clinical Cancer Research 2014, 20: 5041-5051. PMID: 25107914, PMCID: PMC4184913, DOI: 10.1158/1078-0432.ccr-14-0051.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabCisplatinDisease ProgressionFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingRadiotherapyRisk FactorsSquamous Cell Carcinoma of Head and NeckTreatment OutcomeConceptsProgression-free survivalOverall survivalLA-SCCHNMaintenance cetuximabAdvanced squamous cell headMedian progression-free survivalTwo-year overall survivalNeck squamous cell carcinomaTumor human papillomavirus (HPV) statusGrade 5 toxicityMedian overall survivalMedian radiotherapy doseMost common gradeCycles of cisplatinHuman papillomavirus (HPV) statusPhase II studySquamous cell headTumor HPV statusLonger overall survivalSquamous cell carcinomaOropharyngeal primaryHPV statusII studyPrimary endpointProtocol treatmentOropharyngeal squamous cell carcinoma treatment
Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment. Current Opinion In Oncology 2014, 26: 252-258. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/cco.0000000000000072.Peer-Reviewed Original ResearchConceptsHigh-risk human papilloma virusOropharyngeal squamous cell carcinomaHPV-unrelated cancersSquamous cell carcinomaNodal stageCell carcinomaTumor stageSquamous cell carcinoma treatmentHPV-unrelated tumorsAdvanced nodal stageRisk of deathCurrent treatment paradigmsHuman papilloma virusParaffin-embedded tissue blocksImportant causative factorAdvanced nodalDistant diseaseHPV statusCurative therapyFavorable prognosisOropharyngeal cancerRetrospective studyPapilloma virusTreatment paradigmRisk groups
2013
Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression
Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid 2013, 23: 1099-1105. PMID: 23421588, PMCID: PMC3770240, DOI: 10.1089/thy.2013.0027.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAutoantibodiesBiomarkersCarcinomaCarcinoma, PapillaryDisease ProgressionFemaleHumansKaplan-Meier EstimateLogistic ModelsLymph NodesLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisNeck DissectionNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhiladelphiaProportional Hazards ModelsRadiotherapy, AdjuvantReoperationRetrospective StudiesRisk FactorsThyroglobulinThyroid Cancer, PapillaryThyroid NeoplasmsThyroidectomyTime FactorsTreatment OutcomeYoung AdultConceptsComplete biochemical responseMetastatic papillary thyroid carcinomaSystemic disease progressionPapillary thyroid carcinomaExtranodal extensionDisease progressionRAI administrationUntreated patientsNeck dissectionTumor persistenceT4 classificationThyroid carcinomaLong-term clinical outcomesPresence of ENECenter cohort studyGross residual diseaseRadioactive iodine treatmentTherapeutic neck dissectionAnti-thyroglobulin antibodiesRecurrence/persistenceNational Cancer InstituteSuspicious imagingDistant diseaseNodal diseasePrior surgery
2012
Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer
Mehra R, Ang KK, Burtness B. Management of Human Papillomavirus–Positive and Human Papillomavirus–Negative Head and Neck Cancer. Seminars In Radiation Oncology 2012, 22: 194-197. PMID: 22687943, DOI: 10.1016/j.semradonc.2012.03.003.Peer-Reviewed Original ResearchMeSH KeywordsHead and Neck NeoplasmsHumansOropharyngeal NeoplasmsPapillomavirus InfectionsRisk FactorsConceptsHPV-positive diseaseNeck carcinomaClinical trialsHuman papillomavirus-negative headOncogenic human papillomavirus (HPV) infectionPack-year smoking historyCurative treatment regimensHPV-negative diseaseHuman Papillomavirus–PositiveHuman papillomavirus infectionSquamous cell headProspective clinical trialsTraditional risk factorsSquamous cell carcinomaHPV-negative headCurrent clinical trialsCombination of radiationIntermediate riskPapillomavirus infectionSmoking historySystemic therapyTreatment regimensCell carcinomaTransoral surgeryNeck cancer
2011
Psychological functioning of caregivers for head and neck cancer patients
Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY. Psychological functioning of caregivers for head and neck cancer patients. Oral Oncology 2011, 48: 18-25. PMID: 22154127, PMCID: PMC3357183, DOI: 10.1016/j.oraloncology.2011.11.012.Peer-Reviewed Original ResearchConceptsPoor psychological healthPsychological healthPoorer psychological health outcomesCaregivers' psychological healthPsychological health outcomesPsychological functioningAnxious symptomsSocial supportCaregiver outcomesCurrent findingsLongitudinal studyHNSCC patientsFamily caregiversPositive benefitsCaregiversNeck squamous cell carcinomaSquamous cell carcinomaNeck cancer patientsPost-treatment periodHealth outcomesCancer patientsCell carcinomaCancer recurrenceGeneral populationPatients
2008
Head and neck cancers.
Forastiere A, Ang K, Brizel D, Brockstein B, Burtness B, Cmelak A, Colevas A, Dunphy F, Eisele D, Goepfert H, Hicks W, Kies M, Lydiatt W, Maghami E, Martins R, McCaffrey T, Mittal B, Pfister D, Pinto H, Posner M, Ridge J, Samant S, Schuller D, Shah J, Spencer S, Trotti A, Weber R, Wolf G, Worden F. Head and neck cancers. Journal Of The National Comprehensive Cancer Network 2008, 6: 646-95. PMID: 18691457, DOI: 10.6004/jnccn.2008.0051.Peer-Reviewed Original Research
2005
Pregnancy-Associated Breast Cancer
Psyrri A, Burtness B. Pregnancy-Associated Breast Cancer. The Cancer Journal 2005, 11: 83-95. PMID: 15969981, DOI: 10.1097/00130404-200503000-00001.Peer-Reviewed Original ResearchConceptsPregnant breast cancer patientsBreast cancer patientsBreast cancerThird trimesterCancer patientsPregnancy-Associated Breast CancerSubsequent breast cancer developmentBreast massesClinical Oncology meetingsFirst antenatal visitHigh-risk diseaseImpact of pregnancyRisk of recurrenceHigh-risk groupBreast cancer riskPalpable breast massesBRCA2 mutation carriersBreast cancer developmentThorough breast examinationAntenatal visitsBreast conservationClinical presentationSubsequent pregnancyEarly pregnancyOncology meetings
1999
Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.
Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, Kneuper-Hall R, Farber L, Orell J, Bober-Sorcinelli K, Haffty BG, Reiss M. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. The Cancer Journal 1999, 5: 224-9. PMID: 10439168.Peer-Reviewed Original ResearchConceptsBreast cancerDefinitive breast cancer surgeryMetastatic axillary lymph nodesHigh-risk breast cancerMore axillary nodesMyalgia/arthralgiaGrade 3 toxicityNausea/vomitingPercent of patientsAxillary lymph nodesHigh-risk patientsBreast cancer surgeryPreliminary efficacy dataFilgrastim supportNeutropenic feverAcceptable toxicityAdjuvant therapyAxillary nodesDose intensityStandard therapyBone scanLymph nodesCancer surgeryDistant metastasisAcute leukemia